Kelun and Merck's Lung Cancer Drug Improves Survival in Late-Stage China Trial
📊 GOOGL — Piyasa Yorumu
■ neutral · 30%While the news presents a positive development regarding Kelun and Merck's lung cancer drug, no direct impact is expected for GOOGL stock. Since Google's core business operations are not limited to the pharmaceutical sector, it is unlikely that this news will have a meaningful reflection on the stock price. Technical indicators show a weak outlook: RSI is near oversold territory at 38, MACD is below zero, and the price is below both the 20-day and 50-day moving averages. The 3.1% decline in the last 24 hours confirms selling pressure. In the short term, the impact of the news remains limited, while direction uncertainty persists due to the weakness in the technical structure.
📊 KCHOL — Piyasa Yorumu
▲ up · 60%The news announces positive trial results for Merck's lung cancer drug, developed in collaboration with Kelun. While this development could serve as a potential catalyst for KCHOL, the stock closed 3.26% lower in the last session, with RSI at 49 in neutral territory. MACD is negative but approaching the signal line, which may indicate a short-term recovery. A close above SMA20 could strengthen upward momentum.